BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). This product is in Phase IIa trial for patients with T-cell leukemia and a combination IV, and a Phase I pharmacokinetic trial in healthy...